Julie Wolf, PhD

Partner at 2048 Ventures

View Live Interactive Profile →

Biography

Julie Wolf is a Partner at 2048 Ventures, where the firm's team page says she leads the biotech and healthcare verticals and describes her as an investor in more than 50 startups. Before 2048 Ventures she was Chief Science Officer and a member of the founding investment team at SOSV's IndieBio New York. Before entering investing she worked in scientific research, communications and biotech entrepreneurship. She holds a Ph.D. in Microbiology, Immunology, and Cancer Biology from the University of Minnesota and completed a postdoctoral fellowship at Albert Einstein College of Medicine. She is the named author or co-author of the firm's investment announcements for TwoStep Therapeutics, Tetsuwan Scientific, Kascaid, Nionyx Bio and Nimbus Health. No board seat for her was found in any portfolio-company filing or first-party page, so boardSeats is empty.

Education

Previous Experience

Notable Investments

TwoStep TherapeuticsTetsuwan ScientificKascaidNionyx BioNimbus Health

Career Timeline

2024
Authors 2048 Ventures' announcement of its investment in TwoStep Therapeutics, published 25 June 2024.
2024
Co-authors, with Sandra Perez Baos, the firm's announcement of its investment in Tetsuwan Scientific, published 19 November 2024.
2025
Co-authors the firm's announcements of its investments in Kascaid (9 July 2025) and Nionyx Bio (29 September 2025).
2026
Named as one of the firm's three GPs in the 29 January 2026 Fund III announcement.

Sources & References

2048 Ventures - Team (biography and title) ↗2048 Ventures - Our Investment in TwoStep Therapeutics (25 June 2024), authored by Julie Wolf ↗2048 Ventures - Our Investment in Tetsuwan Scientific (19 November 2024), authored by Sandra Perez Baos and Julie Wolf ↗2048 Ventures - Our Investment in Kascaid (9 July 2025), authored by Sandra Perez Baos and Julie Wolf ↗2048 Ventures - Our Investment in Nionyx Bio (29 September 2025), authored by Julie Wolf and Sandra Perez Baos ↗2048 Ventures - Our Investment in Nimbus Health (13 June 2025), authored by Daniella Cohen, Alex Iskold and Julie Wolf ↗2048 Ventures Raises an Oversubscribed $82M Fund III (29 January 2026) ↗